Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health reported a narrower loss on slightly lower revenue for the quarter ended March 31, 2026. Revenue was $613.8M, down 2% from $629.4M a year earlier. Access fees fell to $484.7M, while other revenue, including visit fees and device-related sales, rose to $129.2M.
The net loss improved to $63.8M from $93.0M, with basic and diluted loss per share of $0.36 versus $0.53. This improvement mainly reflects the absence of prior-year goodwill impairment and lower operating expenses, partially offset by higher restructuring charges of $12.0M and higher amortization of intangible assets of $89.8M.
Integrated Care revenue grew 2% to $395.4M, while BetterHelp revenue declined to $218.4M as paying users fell 9% to 0.361 million. Adjusted EBITDA was stable at $58.2M. Teladoc ended the quarter with $750.7M in cash and cash equivalents and $1.0B of 1.25% convertible senior notes due 2027, plus an undrawn $300M revolving credit facility.
Teladoc Health reported First Quarter 2026 revenue of $613.8 million, down 2% from a year earlier, as access-fee revenue declined but other revenue grew. U.S. revenue fell 6% while international revenue rose 17%, reflecting mixed geographic trends.
The company posted a net loss of $63.8 million, or $0.36 per share, improving from a $93.0 million loss last year, helped by the absence of a prior goodwill impairment. Adjusted EBITDA was $58.2 million, essentially flat. Management reaffirmed the midpoint of its full‑year 2026 outlook, including expected revenue of $2.48‑$2.58 billion and positive free cash flow.
Teladoc Health Inc Schedule 13G shows Vanguard Portfolio Management beneficially owns 12,451,266 shares of common stock, representing 6.97% of the class as of 03/31/2026. The filing attributes dispositive power across Vanguard Portfolio Management LLC and affiliated investment divisions and notes 156,172 shares of sole voting power.
Teladoc Health is asking stockholders to vote at its 2026 virtual annual meeting on three main items: electing nine directors, an advisory Say‑on‑Pay vote on executive compensation, and ratifying Ernst & Young LLP as independent auditor for 2026. Only holders of record on March 26, 2026 may vote.
The Board is 89% independent, led by a separate independent chair, and operates through five committees, including Audit, Compensation, Nominating and Corporate Governance, and Quality of Care and Patient Safety. Two new independent directors joined in 2026, bringing average director tenure to six years and average age to 67.
For 2025, Teladoc reported $2.5 billion in total revenue, $281 million in adjusted EBITDA with an 11.1% margin, $781 million in cash and cash equivalents, and $458 million in international revenue, which grew 12%. Executive pay is highly performance‑based: equity and incentives represented 92.9% of the CEO’s target compensation and 83.7% for other named executives, and lower‑than‑target results led to below‑target payouts. The Board recommends voting FOR all management proposals.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity and a small related share sale. On April 1, 2026, restricted stock units converted into 2,083 shares of Teladoc common stock on a one-for-one basis at a conversion price of $0.00.
On April 2, 2026, he sold 675 common shares at $5.114 per share solely to cover the tax withholding obligation tied to the RSU vesting, rather than as a discretionary open-market sale. After these transactions, he directly held 10,249 common shares.
The filing notes that on October 1, 2024, he was granted 25,000 restricted stock units, with one-third vesting on the first anniversary of the grant and the remainder vesting in eight substantially equal quarterly installments thereafter.
SALKA SUSAN R reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Susan R. Salka received a grant of 48,638 restricted stock units (RSUs) linked to Teladoc common stock. Each RSU represents a contingent right to receive one share of common stock. One-third of the RSUs vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter. Following this award, Salka directly holds 48,638 RSUs reported in this filing.
Teladoc Health, Inc. director Susan R. Salka filed an initial Form 3 ownership report. The filing lists her as a director but shows no reportable share transactions or derivative positions, serving mainly as a baseline disclosure of insider status and potential future reporting obligations.
Teladoc Health, Inc. expanded its board of directors to nine members and appointed Susan R. Salka as a new director, effective March 30, 2026. She will serve on the board’s audit and compensation committees, and has been designated an independent director and an “audit committee financial expert.” Ms. Salka is the former president and CEO of AMN Healthcare Services, where over a 33‑year tenure she helped drive 26 acquisitions and grow revenue to over $5 billion. She also brings prior board experience at several major healthcare and life sciences companies.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A reporting on holdings of Teladoc Health Inc. The filing states amount beneficially owned: 0 and percent of class: 0%, reflecting an internal realignment where certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The filing lists Vanguard's address and certifies that no other single person holds more than 5% of the class. The form is signed by Ashley Grim on 03/27/2026.